|
[posting]34464147[/posting]Kaum zu glauben das der Kurs von Labopharm immer noch im keller ist trotz den guten Nachrichten . Die Zulassung ist nur noch eine frage von wenigen Wochen und sehe den aktuellen Kurs als Geschenk an . Also wenn es diesmal nicht klappt obwohl Labopharm sehr eng mit der FDA zusammengearbeitet hat dann geht es nicht mit rechten Dingen zu. Falls die Zulassung kommt : Dann gibts 10 million US$ von Purdue Pharma (Partner für USA) Biovail die dasselbe Produkt haben wobei das von Labopharm effektiver ist macht nach knapp 3 jahren Zulassung rund 100 million US$ Umsatz jährlich . Short interest ist auf Rekordtief http://www.nasdaq.com/aspxcontent/shortinterests.aspx?symbol… ----------- Ich denke mit der Einstellung von Dr. Brulle geht Labopharm den richtigen Weg . 4/28/2008 Labopharm Appoints Dr. Claire Brullé as Senior Vice-President and Chief Medical Officer LAVAL, QC, Apr 28, 2008 (Canada NewsWire via COMTEX News Network) -- - Dr. Sylvie Bouchard to Retire from Company - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that Claire Brullé, M.D. has been appointed Senior Vice-President and Chief Medical Officer of the Company. Incumbent Chief Medical Officer Dr. Sylvie Bouchard has retired from Labopharm Inc. to focus on her career practicing medicine. "Dr. Brullé brings to Labopharm a proven track record in medical affairs and clinical development and an impressive portfolio of competencies ranging from global clinical development to medical support for commercial operations," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "With extensive experience interacting with regulatory agencies in both North America and Europe and specific expertise in the area of pain therapeutics, Dr. Brullé is a strong addition to our team as we pursue our objective of commercializing multiple large market opportunity drugs." Dr. Brullé has more than 25 years experience in the medical profession, including more than 15 years experience in the pharmaceutical industry with Pfizer Inc. During her tenure at Pfizer, Dr. Brullé held a series of increasingly senior medical roles, including lead positions for the Pain and Arthritis Franchise. Dr. Brullé received her Medical Degree from the Université de Paris and has completed International and Leadership Development Programs from INSEAD Institute and Harvard Business School, respectively. Mr. Howard-Tripp continued, "Dr. Bouchard's expertise and diligence has been invaluable to Labopharm's success to date. On behalf of the Company and the Board of Directors, I would like to thank her for her very significant contribution to Labopharm and wish her well as a full-time practicing physician." Dr. Bouchard will continue to be available to Labopharm to transition the role to Dr. Brullé and will act as a consultant to the Company going forward. |
|
| aus der Diskussion: | Labopharm ....Nur geschenkt ist noch billiger |
| Autor (Datum des Eintrages): | BrauchGeld (12.07.08 13:56:30) |
| Beitrag: | 16 von 324 (ID:34494778) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |